Challenges to leveraging real-world evidence for FDA approval

COTA, Panalgo collaborate to enhance AI & RWD-enabled cancer care

COTA joined Panalgo’s Partner Network to make their hematologic oncology data available via Panalgo’s Instant Health Data Analytics platform.

September 13, 2024

Vol.50 No.34

Clinical

RWE study pinpoints gaps in mental health care utilization among parents of children with cancer

Unquestionably, a child’s cancer diagnosis weighs heavily on the parents’ minds. But now, an analysis of nearly 30,000 U.S. families has quantified how often parents of children with cancer use mental health services.

May 17, 2024

Vol.50 No.20

By McKenzie Prillaman

Drugs & Targets

COTA and Sanofi collaborate to accelerate cancer trials using real-world data and AI

COTA, a leader in real-world data and analytics for oncology, is entering a collaboration with Sanofi to use RWD and artificial intelligence to increase the speed of oncology trials, including for multiple myeloma.

April 19, 2024

Vol.50 No.16

Clinical Roundup

Non-classical mutations present in 20-30% of all patients with EGFR-mutated NSCLC, analysis shows

Non-classical mutations are present in 20-30% of all patients with epidermal growth factor receptor-mutated non-small cell lung cancer, according to an analysis of real-world evidence presented by Black Diamond Therapeutics, Inc. at the American Association of Cancer Research annual meeting.

April 12, 2024

Vol.50 No.15

In Brief

Michael Egger, Christopher Manz, Serena Phillips receive 2023 Real-World Data Impact Award from ACS, Flatiron

Michael EggerChristopher ManzSerena PhillipsMichael Egger, Christopher Manz, and Serena Phillips received the 2023 Real-World Data Impact Award from the American Cancer Society and Flatiron Health.

March 08, 2024

Vol.50 No.10

Conversation with The Cancer Letter

Ellen Sigal, Roy Herbst: Friends and FDA to focus on real-world evidence, AI, and streamlined trials in 2024

As artificial intelligence becomes an indispensable tool in cancer research, drug sponsors and researchers should focus on building and utilizing rich real-world evidence databases that can be used to complement clinical trials.

February 09, 2024

Vol.50 No.06

By Paul Goldberg and Matthew Bin Han Ong

Challenges to leveraging real-world evidence for FDA approval

YOU MAY BE INTERESTED IN

COTA, Panalgo collaborate to enhance AI & RWD-enabled cancer care

RWE study pinpoints gaps in mental health care utilization among parents of children with cancer

COTA and Sanofi collaborate to accelerate cancer trials using real-world data and AI

Non-classical mutations present in 20-30% of all patients with EGFR-mutated NSCLC, analysis shows

Michael Egger, Christopher Manz, Serena Phillips receive 2023 Real-World Data Impact Award from ACS, Flatiron

Ellen Sigal, Roy Herbst: Friends and FDA to focus on real-world evidence, AI, and streamlined trials in 2024

Renew today!

Subscriber content

Never miss an issue!

Login